Edwards Lifesciences (EW) Gets a Hold Rating from BTIG
In a report released yesterday, Marie Thibault from BTIG reiterated a Hold rating on Edwards Lifesciences (EW). The company’s shares closed last Thursday at $221.04.
According to TipRanks.com, Thibault is a 2-star analyst with an average return of -4.2% and a 46.7% success rate. Thibault covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings, Varian Medical Systems, and Irhythm Technologies.
Currently, the analyst consensus on Edwards Lifesciences is a Moderate Buy with an average price target of $243.94.
See today’s analyst top recommended stocks >>
Edwards Lifesciences’ market cap is currently $44.89B and has a P/E ratio of 43.70. The company has a Price to Book ratio of 16.94.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into three areas: Transcatheter Heart Valves, Surgical Structural Heart and Critical Care. The Transcatheter Heart Valves portfolio includes technologies designed to treat heart valve disease using catheter-based approaches as opposed to open surgical techniques. Its portfolio includes technologies designed for nonsurgical replacement of heart valves. The Surgical Structural Heart portfolio includes tissue heart valves and heart valve repair products for the surgical replacement or repair of a patient’s heart valve. The Critical Care portfolio products through hemodynamic monitoring system measures a patient’s heart function and fluid status in surgical and intensive care settings. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.